Skip to main content
OpenTrials
Completed

NCT Number: NCT04538157

Comprehensive Geriatric Assessment for Frail Older People With Chronic Kidney Disease - The GOAL Trial

The GOAL trial addresses patient-prioritised research topics and outcomes and will be conducted, disseminated and implemented in partnership with patients and their caregivers. This will be the first study, internationally, to evaluate the clinical and cost effectiveness of Comprehensive Geriatric Assessment (CGA), a highly promising intervention for improving patient-important health outcomes in frail older people with Chronic Kidney Disease (CKD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

55 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Blacktown Hospital, Blacktown, New South Wales, Australia

Loading trial locations.

About this study

There is an increasing number of frail patients with CKD, and multiple morbidities. Many of them face rapid deterioration of health, referral to residential aged care facilities and loss of independence. This substantively impairs their quality of life and has societal ramifications, including very high costs of care. Patients and carers are often overwhelmed by the multitude of decisions they have to make and may follow a care path that is in contrast to their goals.

The GOAL trial addresses patient-prioritised research topics and outcomes and will be conducted, disseminated and implemented in partnership with patients and their caregivers.

The primary objective is to test the hypothesis that in frail older people with stages 3-5 CKD, Comprehensive Geriatric Assessment (compared with usual care) will increase attainment of patient-identified goals at 3 months follow up. The secondary objectives are to test the hypotheses that the Comprehensive Geriatric Assessment will increase attainment of patient-identified goals at 6 and 12 months follow up, improve their quality of life and reduce frailty, hospital and residential aged care facility admissions while being safe and cost-effective.

In this multicentre cluster randomised controlled trial, a total of 500 adult CKD stage 3-5 patients will be recruited. Sites will be randomly allocated to either provide a Comprehensive Geriatric Assessment to participants or usual care. The primary outcome measure is goal attainment scaling at 3 months follow up. The secondary outcome measures will be goal attainment scaling at 6 and 12 months, quality of life EQ-5D-5L, frailty index, mortality, hospital and residential aged care facility admissions and cost-utility analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for screening:

  • Moderate to severe CKD as determined by the treating nephrologist:
  • Stage 3 = eGFR 30 - 59 ml/min/1.73 m2
  • Stage 4 = eGFR 15 - 29 ml/min/1.73 m2
  • Stage 5/5D = eGFR below 15 ml/min/1.73m2, including patients receiving dialysis
  • Aged ≥65 years, or ≥ 55 years if Aboriginal or Torres Strait Islander

For inclusion in enrolment:

  • Frailty Index >0.25 (FI-CKD tool)

Exclusion criteria

  • Estimated life expectancy of less than 12 months.
  • Unable to provide informed consent and/or participate in the Goal Attainment Scaling process due to cognitive impairment or another reason.

Treatment and study plan

Comprehensive Geriatric Assessment

Other

A CGA is a diagnostic and therapeutic intervention which initially identifies an older person's medical, functional, psychosocial problems and then tailors coordinated management plans to address them.

Other names: CGA

Primary outcomes

  1. Goal Attainment Scaling at 3 months

    Time frame: 3 months

    To determine whether CGA in frail older people with stages 3-5 CKD improves attainment of patients' own goals of care at three months.

Secondary outcomes

  1. Goal Attainment Scaling at 6 and 12 months

    Time frame: 6 and 12 months

    To determine whether CGA improves attainments of patients' own goals of care at six and 12 months.

  2. Quality of life using EQ-5D-5L

    Time frame: 3, 6 and 12 months

    To determine whether CGA improved patient's quality of life at three, six and 12 months.Quality of life will be assessed using the EQ-5D-5L

  3. Frailty status

    Time frame: 3, 6 and 12 months

    To determine whether CGA favourably affects the trajectory of frailty status at three, six and 12 months. Frailty will be assessed using the Frailty Index CKD.

  4. Mortality

    Time frame: 12 months

    To determine whether CGA reduces mortality during the 12 months follow-up.

  5. Duration of hospital admissions

    Time frame: 12 months

    To determine whether CGA reduces the duration of hospital admissions during the 12 months follow-up.

  6. Number of hospital admissions

    Time frame: 12 months

    To determine whether CGA reduces the number of hospital admissions during the 12 months follow-up.

  7. Number of residential aged care facility admissions

    Time frame: 12 months

    To determine whether CGA reduces admissions to residential aged care facilities at 12 months follow-up.

  8. Cost-effectiveness

    Time frame: 12 months

    Difference in the incremental cost per Quality Adjusted Life Year gained between treatment arms

Other outcomes

  1. Process evaluation

    Time frame: 12 months

    Qualitative analysis of structured interviews.

Sponsors and collaborators

Lead sponsor

The University of Queensland

Other

Collaborators

  • National Health and Medical Research Council, Australia

Registry information

Official study title

Comprehensive Geriatric Assessment for Frail Older People With Chronic Kidney Disease to Increase Attainment of Patient-Identified Goals - A Cluster Randomised Controlled Trial - The GOAL Trial

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Sep 3, 2020
Registry last updated
Dec 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.